This inventor holds 6 USPTO granted patents and 3 EPO patents. Top assignees: Novartis Ag, Ablynx N.v.. Active years: 2013-2022.
Company Filing History:
Years Active: 2013-2022
Title: Michelle Bradley: Innovator in Chemokine Receptor Research
Introduction
Michelle Bradley is a prominent inventor based in Horsham, GB. She has made significant contributions to the field of biochemistry, particularly in the development of polypeptides that target chemokine receptors. With a total of 6 patents to her name, her work has the potential to impact therapeutic approaches for various diseases.
Latest Patents
Among her latest patents, Michelle has developed innovative chemokine receptor binding polypeptides. These polypeptides are specifically designed to bind to the C–X–C Motif chemokine receptor 2 (CXCR2). The inventions include not only the polypeptides themselves but also nucleic acids, vectors, and host cells capable of expressing these polypeptides. Furthermore, her patents encompass pharmaceutical compositions that utilize these polypeptides for treating diseases associated with the aberrant functioning of CXCR2.
Career Highlights
Throughout her career, Michelle has worked with leading companies in the pharmaceutical industry, including Novartis AG and Ablynx NV. Her experience in these organizations has allowed her to refine her expertise in drug development and biochemistry.
Collaborations
Michelle has collaborated with notable professionals in her field, including Soren Steffensen and Zarin Brown. These partnerships have contributed to her innovative research and the successful development of her patented technologies.
Conclusion
Michelle Bradley stands out as a dedicated inventor whose work in chemokine receptor research is paving the way for new therapeutic solutions. Her contributions to the field are significant and continue to influence advancements in medical science.